ArticleResearch square2022
CD8
Emily S Ford, Koshlan Mayer-Blackwell, Lichen Jing, Anton M Sholukh, Russell St Germain, Emily L Bossard, Hong Xie, Thomas H Pulliam, Saumya Jani, Stacy Selke and 16 more
Open access · greenAbstract readPreprint
In one paragraphArticle in Research square, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed, 4 citations in OpenAlex.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
26 authors.
Emily S Ford
Koshlan Mayer-Blackwell
Lichen Jing
Anton M Sholukh
Russell St Germain
Emily L Bossard
Hong Xie
Thomas H Pulliam
Saumya Jani
Stacy Selke
Carlissa J Burrow
Christopher L McClurkan
Anna Wald
Michael R Holbrook
Brett Eaton
Elizabeth Eudy
Michael Murphy
Elena Postnikova
Harlan S Robins
Rebecca Elyanow
Rachel M Gittelman
Matyas Ecsedi
Elise Wilcox
Aude G Chapuis
Andrew Fiore-Gartland
David M Koelle
Funding
LOC: HIV Vaccine Trials NetworkUM1AI068614 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Dan H. Barouch, Lawrence Corey · 2011 to 2026
$1175.6MUnderstand & overcome resistance to PD-1P01CA225517 · NCI · UNIVERSITY OF WASHINGTON · PI Ted A Gooley · 2019 to 2026
$22.7MInterdisciplinary Tranining in Cancer ResearchT32CA080416 · NCI · UNIVERSITY OF WASHINGTON · PI STODDARD, BARRY L. · 1998 to 2023
$9.7MDECODING THE INTERACTIONS BETWEEN T CELL RECEPTORS AND PEPTIDE-MHCR01AI136514 · NIAID · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI Paul G. Thomas · 2018 to 2026
$6.9MLarge Scale T Cell Epitope Discovery: Local and Systemic T cell Response to Herpes Simplex Virus75N93019C00063 · NIAID · UNIVERSITY OF WASHINGTON · PI MYER, TIM · 2019 to 2023
$5.5MHarnessing Tissue Resident Memory T Cells for Immunotherapy of Herpes Virus InfectionsR01AI134878 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI COREY, LAWRENCE · 2018 to 2022
$3.4MHigh-Performance Compute Cluster for Comprehensive Cancer and Infectious Diseases ResearchS10OD028685 · OD · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BRADLEY, PHILIP · 2020 to 2020
$2.0MHSV-2 specificity and phenotyping of tissue-based T cells in genital skin biopsies of HSV-2 reactivationK08AI148588 · NIAID · UNIVERSITY OF WASHINGTON · PI FORD, EMILY · 2020 to 2024
$947kC19 SARS-CoV-2-specific T cells in the infected nasel epitheliumR21AI163999 · NIAID · UNIVERSITY OF WASHINGTON · PI KOELLE, DAVID M · 2021 to 2022
$485kExhaustion mechanisms in Merkel cell polyomavirus-specific T cellsF30CA254168 · NCI · UNIVERSITY OF WASHINGTON · PI PULLIAM, THOMAS · 2020 to 2023
$168kNCI NIH HHS F30 CA254168NCI NIH HHS P01 CA225517NCI NIH HHS T32 CA080416NIAID NIH HHS 75N93019C00063NIAID NIH HHS HHSN272201800013CNIAID NIH HHS K08 AI148588NIAID NIH HHS R01 AI134878NIAID NIH HHS R01 AI136514NIAID NIH HHS R21 AI163999NIAID NIH HHS UM1 AI068614NIH HHS S10 OD028685
6 · The paper itselfAbstract
Almost three years into the SARS-CoV-2 pandemic, hybrid immunity is highly prevalent worldwide and more protective than vaccination or prior infection alone. Given emerging resistance of variant strains to neutralizing antibodies (nAb), it is likely that T cells contribute to this protection. To understand how sequential SARS-CoV-2 infection and mRNA-vectored SARS-CoV-2 spike (S) vaccines affect T cell clonotype-level expansion kinetics, we identified and cross-referenced TCR sequences from thousands of S-reactive single cells against deeply sequenced peripheral blood TCR repertoires longitudinally collected from persons during COVID-19 convalescence through booster vaccination. Successive vaccinations recalled memory T cells and elicited antigen-specific T cell clonotypes not detected after infection. Vaccine-related recruitment of novel clonotypes and the expansion of S-specific clones were most strongly observed for CD8
Indexed as
clustering analysisimmune repertoiremRNA vaccineSARS-CoV-2T cell receptor
Identifiers
PMID36263073
PMCPMC9580387
OpenAlexW4304091689
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390